Vaccine Tracking Data—The Next Big Alt Dataset
Investment firms and vendors are searching for signals in healthcare and pharmaceutical data in a bid to get a leg up on a Covid-19 vaccine.
One year ago, no one foresaw the coronavirus pandemic and the havoc it would wreak on every aspect of life and work. As fear and anxiety have spread across the globe, it’s becoming increasingly clear that the only way back to “normal” is the development of a drug that combats the Covid-19 virus.
While ordinary people anxiously await a vaccine, the market is transfixed by the idea of a treatment for this highly contagious disease. Investors are keen to bet on which companies will be successful
Only users who have a paid subscription or are part of a corporate subscription are able to print or copy content.
To access these options, along with all other subscription benefits, please contact info@waterstechnology.com or view our subscription options here: http://subscriptions.waterstechnology.com/subscribe
You are currently unable to print this content. Please contact info@waterstechnology.com to find out more.
You are currently unable to copy this content. Please contact info@waterstechnology.com to find out more.
Copyright Infopro Digital Limited. All rights reserved.
As outlined in our terms and conditions, https://www.infopro-digital.com/terms-and-conditions/subscriptions/ (point 2.4), printing is limited to a single copy.
If you would like to purchase additional rights please email info@waterstechnology.com
Copyright Infopro Digital Limited. All rights reserved.
You may share this content using our article tools. As outlined in our terms and conditions, https://www.infopro-digital.com/terms-and-conditions/subscriptions/ (clause 2.4), an Authorised User may only make one copy of the materials for their own personal use. You must also comply with the restrictions in clause 2.5.
If you would like to purchase additional rights please email info@waterstechnology.com
More on Data Management
Data costs rose in 2024, but so did mitigation tools and strategies
Under pressure to rein in data spend at a time when prices and data usage are increasing, data managers are using a combination of established tactics and new tools to battle rising costs.
In 2025, keep reference data weird
The SEC, ESMA, CFTC and other acronyms provided the drama in reference data this year, including in crypto.
Asset manager Saratoga uses AI to accelerate Ridgeline rollout
The tech provider’s AI assistant helps clients summarize research, client interactions, report generation, as well as interact with the Ridgeline platform.
CDOs evolve from traffic cops to purveyors of rocket fuel
As firms start to recognize the inherent value of data, will CDOs—those who safeguard and control access to data—finally get the recognition they deserve?
It’s just semantics: The web standard that could replace the identifiers you love to hate
Data ontologists say that the IRI, a cousin of the humble URL, could put the various wars over identity resolution to bed—for good.
The art of communication: Data pros need better messaging
As the CDO of a tier-one bank puts it, when there’s an imbalance in communication between the data organization and the business (much less other technology heads) “that creates problems.”
Does TP Icap-AWS deal signal the next stage in financial cloud migration?
The IMD Wrap: Amazon’s deal with TP Icap could have been a simple renewal. Instead, it’s the stepping stone towards cloudifying other marketplace operators—and their clients.
T. Rowe Price’s Tasitsiomi on the pitfalls of data and the allures of AI
The asset manager’s head of AI and investments data science gets candid on the hype around generative AI and data transparency.
